Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001246
Publisher
BMJ
Online
2020-10-10
DOI
10.1136/jitc-2020-001246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma
- (2019) Raffit Hassan et al. JAMA Oncology
- Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Ulrich Keilholz et al. Journal for ImmunoTherapy of Cancer
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Hyun Cheol Chung et al. Journal for ImmunoTherapy of Cancer
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
- (2019) Sandra P. D’Angelo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review
- (2018) Omar Abdel-Rahman Immunotherapy
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers
- (2018) Georgia Ritchie et al. JAMA Oncology
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma
- (2016) Guru Sonpavde et al. JOURNAL OF UROLOGY
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Prognostic Value of Pre-operative Renal Insufficiency in Urothelial Carcinoma: A Systematic Review and Meta-Analysis
- (2016) Jian Cao et al. Scientific Reports
- Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
- (2013) Andrea B. Apolo et al. JNCI-Journal of the National Cancer Institute
- Subgroup identification from randomized clinical trial data
- (2011) Jared C. Foster et al. STATISTICS IN MEDICINE
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- (2010) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started